Cladribine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cladribine: From Hairy Cell Leukemia to Parameningeal Embryonal Rhabdomyosarcoma
One-Sentence Summary
Cladribine is a purine nucleoside analog originally used for hairy cell leukemia and relapsing-remitting multiple sclerosis. The TxGNN model predicts it may be effective for parameningeal embryonal rhabdomyosarcoma, but currently there are 0 clinical trials and 0 publications directly supporting this prediction. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hairy cell leukemia, hairy cell leukemia variant, relapsing-remitting multiple sclerosis (the Singapore licence has no indication text on record) |
| Predicted New Indication | Parameningeal embryonal rhabdomyosarcoma |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Cladribine is generally known as a purine nucleoside analog that resists breakdown by adenosine deaminase. It causes DNA strand breaks and apoptosis, mainly in lymphocytes and monocytes, which have high deoxycytidine kinase activity. This explains its use in lymphoid malignancies such as hairy cell leukemia and its immune-modulating effect in multiple sclerosis.
Rhabdomyosarcoma, however, is a solid mesenchymal (soft-tissue) tumour, mostly seen in children. No drug-specific mechanistic rationale or supporting data were found for cladribine in this disease. The high score (about 99.8%) most likely reflects the way rhabdomyosarcoma subtypes cluster together in the knowledge graph, not specific evidence about cladribine. The same pattern applies to the other top-ranked predictions, which are mostly rhabdomyosarcoma subtypes (vaginal, bile duct, prostate and others), plus skeletal muscle neoplasm, gestational trophoblastic neoplasm and pleural adenomatoid tumor.
This prediction should be treated as a hypothesis for further investigation, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top predicted indication.
For context, the only publication retrieved across the predictions concerns a different indication (liver sarcoma, rank 7):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15241520 | 2004 | Case report | Der Hautarzt | Successful cladribine therapy in smoldering systemic mastocytosis. This is not a sarcoma study, so it offers only indirect relevance. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15691P | MAVENCLAD TABLET 10MG | Tablet (oral) | Not recorded in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog / antimetabolite) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions. The knowledge graph links cladribine to neutropenia, thrombocytopenia, anemia and agranulocytosis. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count (with differential), liver and renal function |
| Handling Protection | Follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindications (knowledge graph associations, not package insert text): kidney disease, pyoureter, thrombocytopenia, hyperuricemia, neutropenia, agranulocytosis, peripheral nervous system disease, peripheral neuropathy, anemia, macrocytic anemia.
- Drug Interactions: 100 interactions were found. The main ones are listed below.
- Major: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone), deferiprone, and radiopharmaceuticals or radioimmunotherapy agents (ibritumomab tiuxetan, iobenguane I-131, tositumomab, samarium-153 lexidronam, strontium-89 chloride).
- Moderate: palifermin, dipyridamole, cilostazol, eltrombopag.
Please refer to the package insert for warnings, as label text was not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on model scoring (Evidence Level L5), with no clinical trials or literature for rhabdomyosarcoma and no specific mechanistic rationale. Cladribine is a cytotoxic drug with significant myelosuppression-related safety concerns, and its established activity is in lymphoid disease, not solid tumours.
To proceed, the following is needed:
- Obtain and review the HSA package insert for warnings and contraindications (safety screening cannot proceed without it)
- Detailed mechanism of action data (MOA)
- Preclinical data (e.g., cell-line or xenograft studies) showing cladribine activity in rhabdomyosarcoma
- A systematic literature and trial registry search specific to cladribine and rhabdomyosarcoma
- Assessment of route compatibility (the Singapore product is an oral tablet) and of whether the indication fits the approved dose regimen
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.